M.A. AFANASYEVA¹, I.Yu. KHAYRUTDINOVA², S.A. LAPSHINA², E.V. SUKHORUKOVA¹, R.Z. ABDRAKIPOV¹, Ya.O. SHEVNINA^1,2, Z.N. GARAEVA², D.I. ABDULGANIYEVA^1,2

¹Republic Clinical Hospital of the MH of RT, 138 Orenburgskiy Trakt, Kazan, Russian Federation, 420064

²Kazan State Medical University, 49 Butlerov Str., Kazan, Russian Federation, 420012

 Afanasyeva M.A. ― doctor of the Rheumatology Department, tel. (843) 231-21-67, e-mail: afmaria2108@mail.ru

Khairutdinova I.Yu. ― resident doctor of the Department of Hospital Therapy, tel. +7-937-579-79-99, e-mail: irishka.nout@mail.ru

Lapshina S.A. ― Cand. Med. Sc., Assistant of the Department of Hospital Therapy, tel. (843) 237-34-83, e-mail: svetlanalapshina@mail.ru

Sukhorukova E.V. — doctor of the Rheumatology Department, tel. (843) 231-21-67, e-mail: s-elena1407@mail.ru

Abdrakhipov R.Z. ― Head of the Rheumatology Department, tel. (843) 231-21-67, e-mail: hosptherapy@mail.ru

Shevnina Ya.O. ― resident doctor of the Department of Hospital Therapy, tel. (843) 231-21-67, e-mail: janashevnina1@gmail.com

Garaeva Z.N. ― resident doctor of the Department of Hospital Therapy, tel. (843) 237-34-83, e-mail: zulfia1893@gmail.com

Abdulganiyeva D.I. ― D. Med. Sc., Professor, Head of the Department of Hospital Therapy, tel. (843) 237-34-83, e-mail: diana_s@mail.ru

 The article presents the results of long-term dynamic examination of 6 patients (2 men, 4 women) with a reliable diagnosis of granulomatosis with polyangiitis (GPA) with various clinical manifestations and severe course of the disease, who received rituximab (RTM) for a period of 1 to 3 years. The results were evaluated by the end of the first year of treatment. Against the background of therapy, there was a positive clinical effect, a decrease in the laboratory activity of the disease, and a decrease in the dose of glucocortico-steroids (GCS). Five patients are in drug-induced clinical remission. The article also presents a clinical case of one of the patients. The use of RTM in patients with GPA can provide a positive clinical effect and remission of the disease, provided the diagnosis is stated timely.

Key words: systemic vasculitis associated with antineutrophilic cytoplasmic antibodies; microscopic polyangiitis; rituximab.

 REFERENCES

1. Basu N., Watts R., Bajema I., et al. EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Ann. Rheum. Dis, 2010, 69, pp. 1744-50. doi: 10.1136/ard.2009.119032
2. Federal’nye klinicheskie rekomendatsii po diagnostike i lecheniyu sistemnykh vaskulitov, 2013 [Federal clinical guidelines for the diagnosis and treatment of systemic vasculitis, 2013].
3. Nasonov E.L., Beketova T.V. ANTsA-assotsiirovannye sistemnye vaskulity [ANCA-associated systemic vasculitis], available at: http://roche.xpractice.ru/app/xdata/dst/mabtheravaskulit/pdf/Brochure_Vaskulit.pdf
4. Yates M., Watts R.A., Bajema I.M., et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann. Rheum. Dis, 2016, Jun 23, doi: 10.1136/annrheumdis-2016-209133.
5. Ntatsaki E., Carruthers D., Chakravarty K., et al. BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxford), 2014, 53 (12), pp. 2306-9. doi: 10.1093/rheumatology/ket445
6. Guillevin L., Cordier J., Lhote F., et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide in the treatment of generalized Wegener’s granulomatosis. Arthritis Rheum, 1997, 40, pp. 2187-98. doi: 10.1002/art.1780401213
7. Beketova T.V. The significance of the national register of patients with ANCA-associated systemic vasculitis as an innovative tool for personified induction and maintenance therapy. Nauchno-prakticheskaya revmatologiya, 2016, 54 (5), pp. 499-507 (in Russ.). DOI:10.14412/1995-4484-2016-499-507
8. Beketova T.V. European (EULAR / ERA-EDTA) recommendations for the diagnosis and treatment of ANCA-associated systemic vasculitis-2016. Nauchno-prakticheskaya revmatologiya, 2017, 55 (1), pp. 12-16 (in Russ.). DOI:10.14412/1995-4484-2017-12-16
9. De Groot K., Harper L., Jayne D.R. et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized rial. Ann. Intern. Med, 2009, 150, pp. 670-80. doi: 10.7326/0003-4819-150-10- 200905190-00004
10. Guillevin L., Cordier J.F., Lhote F., et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener’s granulomatosis. Arthritis Rheum, 1997, 40, pp. 2187-98. doi: 10.1002/1529-0131(199712)40:123.0.CO;2-H 7.
11. Harper L., Morgan M.D., Walsh M., et al. Pulse versus daily oral cyclophosphamide for nduction of remission in ANCA-associated vasculitis: long-term follow-up. Ann. Rheum. Dis, 2012, 71, pp. 955-60. doi: 10.1136/annrheumdis-2011-200477 8.
12. Jones R.B., Tervaert J.W., Hauser T., et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N.Engl.J.Med, 2010, 363, pp. 211-20. doi: 10.1056/NEJMoa0909169 9.
13. Stone J.H., Merkel P.A., Spiera R., et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med, 2010, 363, pp. 221-32. doi: 10.1056/NEJMoa0909905.
14. Hellmich B., Flossmann O., Gross W.L., et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody associated vasculitis. Ann. Rheum. Dis, 2007, 66, pp. 605-17. doi: 10.1136/ard.2006.062711
15. Beketova T.V., Aleksandrova E.N., Novoselova T.M. et al. Russian experience of using monoclonal antibodies to B-lymphocytes (rituximab) in systemic vasculitis associated with antineutrophil cytoplasmic antibodies (preliminary results of the Russian register NORM). Nauchno-prakticheskaya revmatologiya, 2014, 52 (2), pp. 147-158. DOI:10.14412/1995-4484-2014-147-158 (in Russ.).
16. Jones R., Cohen Tervaert J., Hauser T. et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N.Engl.J.Med, 2010, 363 (3), pp. 211-20. DOI: 10.1056/NEJMoa0909169.
17. Jones R.B., Walsh M., Jayne D.R.W., et al. Two-year follow-up results from a randomized trial of RTX versus CyP for ANCA-associated renal vasculitis: RITUXVAS. Clin. Exp. Immunol, 2011, 164, p. 57.
18. Stone J., Merkel P., Spiera R., et al. RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vas- colitis. N. Engl. J. Med, 2010, 363 (3), pp. 221-32. DOI: 10.1056/NEJMoa0909905.
19. Specks U., Stone J.H. the RAVE-ITN Research Group. Long-term efficacy and safety results of the RAVE trial. Clin. Exp. Immunol, 2011, 164, p. 65.